Burning Rock Biotech (BNR) Current Leases (2019 - 2026)

Burning Rock Biotech's Current Leases history runs 8 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Current Leases fell 1.39% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 1.39% YoY), while the FY2025 annual figure was $2.4 million, down 28.79% from the prior year.
• Current Leases for Q1 2026 stood at $3.1 million, up from $2.4 million in the prior quarter.
• The five-year high for Current Leases was $5.7 million in Q2 2022, with the low at $1.2 million in Q4 2023.
• The 5-year median for Current Leases is $3.2 million (2023), against an average of $3.5 million.
• The sharpest annual moves came in 2023 and 2024: Current Leases slumped 77.1% in 2023, then surged 185.21% in 2024.
• Burning Rock Biotech's Current Leases stood at $5.2 million in 2022, then plunged by 77.1% to $1.2 million in 2023, then soared by 185.21% to $3.4 million in 2024, then sank by 30.9% to $2.4 million in 2025, then climbed by 29.52% to $3.1 million in 2026.
• Business Quant data shows BNR's Current Leases at $3.1 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.